GlassScriptPhysician profile
Danny Meslemani
NPI 1447460134
$16,244.31
in general payments reported to CMS, 2019-2025
27 companies · $3,320 in 2025
The $3,320 reported for 2025 was more than what 94% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,510 · 2020: $483 · 2021: $331 · 2022: $1,680 · 2023: $3,268 · 2024: $5,654 · 2025: $3,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Travel and Lodging: $667 · Education: $57.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,516.09 |
| Travel and Lodging | $667.40 |
| Education | $57.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurent Medical Limited | $6,884.04 | 2022-2025 | Neuromark Radiofrequency Console, Neuromark Device, Neuromark System |
| Aerin Medical INC. | $3,523.59 | 2021-2025 | |
| Stryker Corporation | $1,450.11 | 2019-2021 | |
| Glaxosmithkline, LLC. | $782.58 | 2021-2025 | Nucala |
| Genzyme Corporation | $658.81 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $657.89 | 2020-2025 | Dupixent |
| Optinose US, INC. | $429.42 | 2019-2025 | |
| Spirair, INC. | $248.20 | 2025 | |
| Arrinex, INC. | $190.45 | 2019 | |
| Amgen INC. | $169.37 | 2023-2025 | Tezspire |
| Hikma Pharmaceuticals USA | $168.27 | 2023-2025 | Ryaltris |
| Medtronic, INC. | $163.46 | 2021-2025 | Stealthstation S8 Platform, Propel, Nuvent |
| Alk-Abello, INC | $130.75 | 2021-2025 | Odactra, Grastek, Ragwitek |
| Kaleo, INC. | $123.03 | 2023-2024 | Auvi-Q |
| Intersect Ent, INC. | $120.81 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $96.22 | 2022-2025 | Trudi Probe, Relieva Spinplus Nav, Inspira Air |
| Acclarent, INC | $86.46 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $85.44 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $66.11 | 2022-2023 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $43.36 | 2025 | Neffy |
| Phadia US INC. | $33.61 | 2023-2024 | Immunocap |
| Abbvie INC. | $30.99 | 2024 | |
| Pfizer INC. | $22.81 | 2023 | |
| Incyte Corporation | $22.49 | 2024 | Opzelura |
| Biocryst US Sales Co., LLC | $21.44 | 2025 | Orladeyo |
| Acelrx Pharmaceuticals, INC. | $19.51 | 2022 | |
| Genentech USA, INC. | $15.09 | 2025 | Xolair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Meslemani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.